DENND2A Inhibitors
DENND2A inhibitors are a class of chemical compounds specifically designed to hinder the activity of the DENND2A protein, a guanine nucleotide exchange factor (GEF) known for its role in regulating the activation of Rab proteins, which are small GTPases involved in vesicular trafficking. These inhibitors work by directly interfering with the GEF activity of DENND2A, thereby preventing the exchange of GDP for GTP on Rab proteins, a critical step required for their activation. Without this exchange, the Rab proteins remain in their inactive GDP-bound state, leading to a disruption in the intracellular trafficking processes they govern. The precise mechanisms by which these inhibitors bind to and inhibit DENND2A are varied and depend on the chemical structure of the specific inhibitor in question. Some may mimic the substrate's structure, competing with GDP or GTP for binding to the active site, while others may bind to allosteric sites that induce conformational changes in DENND2A, reducing its affinity for Rab proteins, or impeding its ability to catalyze nucleotide exchange.
The inhibition of DENND2A has downstream effects on cellular trafficking pathways, notably impacting processes such as endocytosis, exocytosis, and the recycling of membrane receptors, which are vital for maintaining cellular homeostasis. DENND2A inhibitors can therefore profoundly affect cellular signaling and the distribution of membrane proteins. The specificity of these inhibitors lies in their ability to target DENND2A without affecting other GEFs or GTPases, which allows for a more nuanced approach in studying the pathways mediated by DENND2A. This specificity is crucial, as it minimizes off-target effects and allows researchers to dissect the role of DENND2A in cellular processes with greater precision. By impeding the activation of Rab proteins via DENND2A inhibition, these chemical compounds offer valuable insight into the fundamental cellular mechanisms that underpin vesicular trafficking and the maintenance of cellular organization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. DENND2A is involved in the regulation of EGFR trafficking. By inhibiting EGFR, Erlotinib may decrease the functional activity of DENND2A as it has less substrate to act upon, leading indirectly to its inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR tyrosine kinase inhibitor. Similar to Erlotinib, it inhibits the EGFR signaling pathway. Since DENND2A is implicated in the endocytic recycling of EGFR, Gefitinib's action would lead to reduced availability of EGFR for DENND2A to interact with, indirectly inhibiting DENND2A's role in this process. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that acts on both EGFR and HER2/neu receptors. By impeding the activity of these receptors, Lapatinib would indirectly inhibit DENND2A by reducing the receptors' endocytic recycling, a process in which DENND2A is involved. | ||||||
Canertinib | 267243-28-7 | sc-207397 | 10 mg | $260.00 | 3 | |
CI-1033 is a pan-erbB tyrosine kinase inhibitor. It broadly inhibits receptors of the EGFR family. DENND2A, which is involved in regulating EGFR endocytic trafficking, would be indirectly inhibited due to the decreased functional activity of the EGFR family of receptors. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a small molecule that inhibits dynamin, a GTPase involved in endocytic vesicle scission. Since DENND2A is associated with the trafficking of endocytic vesicles, inhibition of dynamin could lead to a buildup of trafficking intermediates, thereby indirectly inhibiting DENND2A by reducing its substrate availability. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a vacuolar H+-ATPase inhibitor that blocks endosomal acidification. This could lead to the impairment of the endocytic pathway, where DENND2A operates. Consequently, DENND2A's functional activity may be indirectly decreased due to the impaired endocytic trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts endosomal pH gradients. By altering the endosomal environment, it could indirectly affect DENND2A function by disrupting the trafficking of vesicles it is involved with, due to pH-dependent sorting mechanisms being impaired. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can also affect EGFR activity. By inhibiting EGFR, Genistein can indirectly limit the functional role of DENND2A in EGFR recycling, leading to a decrease in DENND2A-mediated trafficking processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor known to affect c-Abl and the PDGF receptors. DENND2A has been proposed to interact with molecules in similar pathways. By inhibiting these kinases, Imatinib may lead to reduced signaling through these pathways, indirectly decreasing the functional activity of DENND2A. | ||||||
Dynamin Inhibitor II | 1119-97-7 | sc-203931 sc-203931A sc-203931B sc-203931C | 25 g 250 g 500 g 1 kg | $47.00 $84.00 $124.00 $198.00 | ||
MiTMAB is a dynamin inhibitor like Dynasore, and it prevents the scission of clathrin-coated vesicles from the membrane. Inhibition of dynamin function would result in the accumulation of vesicular intermediates. | ||||||